Isu Abxis Co Ltd
KOSDAQ:086890
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 930
7 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Isu Abxis Co Ltd
Cost of Revenue
Isu Abxis Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Isu Abxis Co Ltd
KOSDAQ:086890
|
Cost of Revenue
-₩17.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-18%
|
|
|
Celltrion Inc
KRX:068270
|
Cost of Revenue
-₩1.5T
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-31%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cost of Revenue
-₩227.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Cost of Revenue
-₩85.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cost of Revenue
-₩85.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cost of Revenue
-₩42.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Isu Abxis Co Ltd
Glance View
ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.
See Also
What is Isu Abxis Co Ltd's Cost of Revenue?
Cost of Revenue
-17.2B
KRW
Based on the financial report for Jun 30, 2024, Isu Abxis Co Ltd's Cost of Revenue amounts to -17.2B KRW.
What is Isu Abxis Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-18%
Over the last year, the Cost of Revenue growth was 38%. The average annual Cost of Revenue growth rates for Isu Abxis Co Ltd have been -7% over the past three years , -10% over the past five years , and -18% over the past ten years .
You don't have any saved screeners yet
